Expert Interviews

In this first of three-part video series, Craig Samitt, CEO and president of Blue Cross Blue Shield of Minnesota talks with MHE about healthcare utilization among its members and the elimination of low-value care.

Thomas P. Leist, MD, PhD, explains that there is no such thing as "one size fits all" for patients with SPMS. Patients can be impacted differently based on how they present themselves and how they behave.

Fred Lublin, MD, says a new labeling indication of Secondary Progressive Multiple Sclerosis broadens whom you can treat. He adds this will be very helpful to patients because it will treat groups that are progressing slowly without agents of activity.

The five states have moved to prohibit accumulators and maximizers as the federal government takes a hands-off approach, according to John “Jack” S. Linehan, a lawyer at Epstein Becker Green, who is featured in this second part of a two-part video series.

Thomas P. Leist, MD, PhD, says doctors working with patients diagnosed with SPMS don't necessarily have prognostic biomarkers to detect SPMS. The best prognostic biomarkers they have currently are MRI and potentially neurofilament light. He adds their techniques need to improve in order to harness the full benefit of potentially individualizing care to the most optimal fashion in a given patient.

John “Jack” S. Linehan, a lawyer at Epstein Becker Green, is featured in the first part of a two-part video series on copay accumulators and maximizers.

Thomas P. Leist, MD, PhD, discusses secondary progressive MS, more specifically how very early control of the disease gives the patient the best chance for long term stability and gives the patient, the best chance of not entering the secondary state.

Fred Lublin, MD, says it's possible health professionals can develop some biomarkers and find some differences in advanced MRI metrics in finding Secondary Progressive Multiple Sclerosis.

In this second of a two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says he is in favor of extending CMS waivers that made telehealth visits reimbursable and easy for patients and providers.

In this first of two-part video interview with MHE, Amwell Chief Medical Officer Peter Antall says the Boston-based telehealth company typically white labels its software to a client’s brand.

The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.

“Lung cancer screening is a great example of the problem,” says the former chief medical and scientific officer for the American Cancer Society in this third of four-part video series.

The Johns Hopkins professor and new MHE editorial advisory board member lauds the effects of the Affordable Care Act but holds out for a program that “gets every human being the healthcare that every human being deserves,” in this second part of a four-part series.

Featured speaker at the 4th Annual PBMI Specialty Rx Forum on October 16 discusses theme of the meeting.

Some “don’t give a damn about their fellow man.” But in this first of four-part video series, the Johns Hopkins professor, former chief medical and scientific officer of the American Cancer Society, and MHE Editorial Advisory Board member is encouraged by diversity among protestors and the broadening of the efforts to tackle disparities of all kinds. “I think this is a long-term effort.”

Penn’s Amol Navathe, M.D., Ph.D., and colleagues reported favorable results in Health Affairs. Navathe is featured in this second of a two part video series.